FdaApplication
NDA 204275
Identifiers
- fda_app_no: NDA204275
Properties
| Property | Value |
|---|---|
| applicant_name | GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE |
| application_type | NDA |
| approval_date | 2013-05-10 |
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | 0.1MG/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | 0.05MG/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | 0.2MG/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION |
3 products